David Wood's Insider Trades & SAST Disclosures
David Wood's most recent trade in Cummins Inc. was a trade of 1,155 Common done . Disclosure was reported to the exchange on March 1, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern David Wood.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cummins Inc. | Jonathan David Wood | Vice President & CTO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 1,155 | 3,731 (0%) | 0% | 0 | Common | |
| Cummins Inc. | Jonathan David Wood | Vice President & CTO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 368.18 per share. | 01 Mar 2025 | 543 | 3,188 (0%) | 0% | 368.2 | 199,922 | Common |
| Agilysys, Inc | William David Wood | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 134.01 per share. | 02 Dec 2024 | 1,870 | 47,609 (0%) | 0% | 134.0 | 250,599 | Common Stock |
| Agilysys, Inc | William David Wood | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Nov 2024 | 4,015 | 4,015 | - | - | Restricted Stock Units | |
| Agilysys, Inc | William David Wood | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 100.86 per share. | 01 Nov 2024 | 588 | 49,479 (0%) | 0% | 100.9 | 59,306 | Common Stock |
| Agilysys, Inc | William David Wood | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 102.03 per share. | 01 Jul 2024 | 163 | 50,228 (0%) | 0% | 102.0 | 16,631 | Common Stock |
| Agilysys, Inc | William David Wood | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 102.78 per share. | 01 Jul 2024 | 161 | 50,067 (0%) | 0% | 102.8 | 16,548 | Common Stock |
| Surrozen Inc | David J. Woodhouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 1,333 | 1,333 | - | - | Option (right to buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 500,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 500,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 500,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 450,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 400,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 381,600 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 255,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 200,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | 05 Apr 2024 | 97,654 | 0 (0%) | 0% | - | Common Stock | ||
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 95,400 | 0 | - | - | Restricted Stock Unit | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 87,013 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 57,833 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | 05 Apr 2024 | 23,993 | 0 (0%) | 0% | - | Common Stock | ||
| Essa Pharma Inc | David Wood | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2024 | 110,000 | 110,000 | - | - | Options | |
| Cummins Inc. | Jonathan David Wood | Vice President & CTO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 1,170 | 3,126 (0%) | 0% | 0 | Common | |
| Cummins Inc. | Jonathan David Wood | Vice President & CTO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 270.26 per share. | 01 Mar 2024 | 550 | 2,576 (0%) | 0% | 270.3 | 148,643 | Common |
| Cummins Inc. | David Jonathan Wood | Vice President & CTO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 2,665 | 0 | - | - | Stock Option (Right-to-Buy) | |
| Cummins Inc. | Wood Jonathan David | Vice President & CTO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 142.12 per share. | 15 Feb 2024 | 2,665 | 3,968 (0%) | 0% | 142.1 | 378,750 | Common |
| Cummins Inc. | Wood Jonathan David | Vice President & CTO | Sale of securities on an exchange or to another person at price $ 264.91 per share. | 15 Feb 2024 | 2,012 | 1,956 (0%) | 0% | 264.9 | 533,003 | Common |
| Agilysys, Inc | Wood William David | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 85.45 per share. | 29 Jan 2024 | 10,000 | 50,391 (0%) | 0% | 85.5 | 854,500 | Common Stock |
| Ngm Biopharmaceuticals Inc | David Woodhouse J. | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.34 per share. | 16 Jan 2024 | 13,032 | 131,822 (0%) | 0% | 1.3 | 17,463 | Common Stock |
| Agilysys, Inc | Wood David William | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 86.33 per share. | 05 Dec 2023 | 760 | 60,391 (0%) | 0% | 86.3 | 65,611 | Common Stock |
| Agilysys, Inc | William David Wood | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 85.90 per share. | 01 Dec 2023 | 363 | 61,151 (0%) | 0% | 85.9 | 31,182 | Common Stock |
| Agilysys, Inc | William David Wood | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.64 per share. | 30 Jun 2023 | 480 | 57,502 (0%) | 0% | 68.6 | 32,947 | Common Stock |
| Surrozen Inc | David J. Woodhouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 20,000 | 20,000 | - | - | Option (right to buy) | |
| Agilysys, Inc | William David Wood | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 82.51 per share. | 31 Mar 2023 | 116 | 57,982 (0%) | 0% | 82.5 | 9,571 | Common Stock |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 381,600 | 381,600 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 127,200 | 144,854 (0%) | 0% | 0 | Common Stock | |
| Cummins Inc. | Jonathan David Wood | Vice President & CTO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 513 | 1,545 (0%) | 0% | 0 | Common | |
| Cummins Inc. | Jonathan David Wood | Vice President & CTO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 249.21 per share. | 01 Mar 2023 | 242 | 1,303 (0%) | 0% | 249.2 | 60,309 | Common |
| Agilysys, Inc | William David Wood | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2023 | 39,087 | 82,065 (0%) | 0% | 0 | Common Stock | |
| Agilysys, Inc | William David Wood | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2023 | 39,087 | 0 | - | - | Stock-Settled Appreciation Rights | |
| Agilysys, Inc | William David Wood | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.02 per share. | 27 Jan 2023 | 32,292 | 64,098 (0%) | 0% | 83.0 | 2,680,882 | Common Stock |
| Agilysys, Inc | William David Wood | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2023 | 14,325 | 2,528 | - | - | Stock-Settled Appreciation Rights | |
| Agilysys, Inc | William David Wood | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2023 | 14,325 | 96,390 (0%) | 0% | 0 | Common Stock | |
| Agilysys, Inc | William David Wood | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 83.94 per share. | 27 Jan 2023 | 6,000 | 58,098 (0%) | 0% | 83.9 | 503,640 | Common Stock |
| Agilysys, Inc | William David Wood | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2023 | 4,640 | 41,981 (0%) | 0% | 0 | Common Stock | |
| Agilysys, Inc | William David Wood | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2023 | 4,640 | 0 | - | - | Stock-Settled Appreciation Rights | |
| Agilysys, Inc | William David Wood | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2023 | 997 | 42,978 (0%) | 0% | 0 | Common Stock | |
| Agilysys, Inc | William David Wood | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2023 | 997 | 0 | - | - | Stock-Settled Appreciation Rights | |
| Essa Pharma Inc | David Wood | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.60 per share. | 30 Dec 2022 | 8,302 | 33,343 (0%) | 0% | 2.6 | 21,585 | Common Shares |
| Agilysys, Inc | William David Wood | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.14 per share. | 30 Dec 2022 | 77 | 37,341 (0%) | 0% | 79.1 | 6,094 | Common Stock |
| Agilysys, Inc | William David Wood | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 65.05 per share. | 12 Nov 2022 | 1,691 | 37,418 (0%) | 0% | 65.1 | 110,000 | Common Stock |
| Agilysys, Inc | William David Wood | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 55.35 per share. | 30 Sep 2022 | 77 | 35,727 (0%) | 0% | 55.4 | 4,262 | Common Stock |
| Agilysys, Inc | William David Wood | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.27 per share. | 01 Jul 2022 | 77 | 35,804 (0%) | 0% | 47.3 | 3,640 | Common Stock |
| Essa Pharma Inc | David Wood | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2022 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Agilysys, Inc | William David Wood | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2022 | 5,434 | 0 | - | - | Stock-settled Appreciation Rights | |
| Agilysys, Inc | William David Wood | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2022 | 5,434 | 38,437 (0%) | 0% | 0 | Common Stock | |
| Agilysys, Inc | William David Wood | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.62 per share. | 15 Jun 2022 | 2,556 | 35,881 (0%) | 0% | 39.6 | 101,269 | Common Stock |
| Agilysys, Inc | William David Wood | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 43.06 per share. | 08 Jun 2022 | 3,193 | 33,003 (0%) | 0% | 43.1 | 137,491 | Common Stock |
| Surrozen Inc | David J. Woodhouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 20,000 | 20,000 | - | - | Option (right to buy) | |
| Agilysys, Inc | William David Wood | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 40.07 per share. | 01 Apr 2022 | 329 | 30,137 (0%) | 0% | 40.1 | 13,183 | Common Stock |
| Agilysys, Inc | William David Wood | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 40.83 per share. | 01 Apr 2022 | 327 | 29,810 (0%) | 0% | 40.8 | 13,351 | Common Stock |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.70 per share. | 29 Dec 2021 | 12,987 | 12,987 (0%) | 0% | 7.7 | 100,000 | Common Stock |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Dec 2021 | 12,987 | 87,013 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Dec 2021 | 4,667 | 57,833 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.14 per share. | 29 Dec 2021 | 4,667 | 17,654 (0%) | 0% | 8.1 | 37,989 | Common Stock |
| Agilysys, Inc | William David Wood | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.96 per share. | 31 Mar 2021 | 979 | 21,719 (0%) | 0% | 48.0 | 46,953 | Common Stock |
| Ngm Biopharmaceuticals Inc | David J. Woodhouse | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2021 | 450,000 | 450,000 | - | - | Stock Option (Right to Buy) | |
| Gulfport Energy Corp. - Or... | David M. Wood | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.09 per share. | 26 Feb 2021 | 49,845 | 307,208 (0%) | 0% | 0.1 | 4,376 | Common Stock |
| Agilysys, Inc | William David Wood | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2020 | 39,087 | 39,087 | - | - | Stock Appreciation Rights | |
| Agilysys, Inc | William David Wood | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2020 | 16,853 | 16,853 | - | - | Stock Appreciation Rights | |
| Agilysys, Inc | William David Wood | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2020 | 2,997 | 22,698 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges